Lydia van Maanen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Abstract Background. Eniluracil is an inactivator of dihydropyrimidine dehydrogenase, the first enzyme in the catabolic pathway of 5-fluorouracil (5-FU). Concurrent administration of oral eniluracil with oral 5-FU not only increases the bioavailability of 5-FU, owing to elimination of first-pass metabolism, but can change the route of elimination of 5-FU(More)
  • 1